News

Home>News
News2020-07-17T11:41:26-04:00
Jan 252022

Halberd CEO Letter: 2021 Year-End & 2022 Outlook

January 25th, 2022|Categories: Investor News, Press Releases, Update Letter|Tags: |

Jackson Center, PA, January 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) First of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year! 2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is a huge worldwide demand for cures to long standing diseases; There is no effective cure available; Big Pharma had either ...

Jan 52022

Halberd Corporation Now an Official US Government Contractor

January 5th, 2022|Categories: Investor News, News, Press Releases|Tags: , , , , , |

Halberd to bid on Additional Federal Contracts with the Federal Government Jackson Center, PA, January 5, 2022 – Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government’s System for Award Management allowing Halberd to bid on Federal contracts and conduct business with the Federal government in the areas of Research and Development in Biotechnology, and Food (Health) Supplement Stores.  This opens the door to Halberd to provide products and services to members of ...

Dec 202021

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

December 20th, 2021|Categories: Investor News, Medical, News|Tags: , , , , , , , |

Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below).  Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer’s Disease is not very well established.  It may cause neurodegeneration as well ...

Dec 152021

Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

December 15th, 2021|Categories: Investor News, Medical, News|Tags: , , , , , , , , |

Jackson Center, PA, December 15, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer’s Disease or mild cognitive impairment.  Halberd’s demonstrated ability to control the levels of IL-12, along with other inflammatory cytokines and antigens in CSF, is intended to slow or prevent the onset ...

Dec 132021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

December 13th, 2021|Categories: Featured, Investor News, Medical, News, Press Releases|Tags: , , , , , , , , , , , |

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease.   Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous successful elimination of TNF-alpha and other inflammatory cytokines and antigens from CSF, the company believes it has achieved  unparalleled progress ...

Dec 62021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

December 6th, 2021|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , , , , , , , , , |

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).  These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation.  TNF-alpha is an inflammatory cytokine which has been identified as a major contributor to Alzheimer’s Disease, and recently has been linked to PTSD/Chronic Traumatic Encephalopathy ...

Go to Top